NOVOCURE LTD (NVCR)
Sector: Health Care
2025 Annual Meeting Analysis
NOVOCURE LTD · Meeting: June 4, 2025
Directors FOR
3
Directors AGAINST
8
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Mr. Danziger has served on the board since 2012 and his tenure fully overlaps with NovoCure's severe stock underperformance. The company's 3-year stock return of -81.9% trails the company's own disclosed peer group median by 44.4 percentage points, well above the 20-point trigger threshold that applies when absolute returns are negative. The 5-year TSR gap of -41.1pp also exceeds the threshold, confirming this is sustained rather than transient underperformance, so the 5-year mitigant does not apply.
Mr. Doyle has served as a director since 2004 and Executive Chairman since 2016, giving him full overlap with NovoCure's prolonged stock decline. The company's 3-year return of -81.9% lags the company-disclosed peer group median by 44.4 percentage points, far exceeding the 20-point trigger for directors with long tenure and negative absolute returns. The 5-year comparison shows an even deeper loss (-92.0% absolute), confirming the underperformance is not a recent blip, so no mitigant applies.
Ms. Hilleman has served since 2018, fully overlapping with the 3-year underperformance window. NovoCure's stock fell 81.9% over three years while the IHI — iShares US Medical Devices ETF was essentially flat (-0.3%), a gap of 81.6 percentage points that far exceeds the 30-point ETF fallback threshold. The peer-group gap of 44.4 points also exceeds the 20-point named-peer threshold, and the 5-year record does not provide relief as that gap also exceeds the threshold.
Dr. Hung has served since 2018, fully overlapping with the 3-year underperformance period. The 3-year peer-group gap of -44.4 percentage points exceeds the 20-point trigger, and the 5-year gap of -41.1 points also exceeds the same threshold, so no mitigation applies. As a sitting CEO of Nuvation Bio, Dr. Hung's outside board commitments appear limited to one public board seat at NovoCure, so overboarding is not a separate concern.
Mr. Leung has been on the board since 2011, giving him the longest independent-director tenure on the slate and full overlap with the underperformance period. The 3-year peer-group TSR gap of -44.4 percentage points and the IHI — iShares US Medical Devices ETF gap of -81.6 percentage points both far exceed their respective thresholds, and the 5-year record offers no relief.
Mr. Madden has served since 2017, giving him full tenure overlap with the 3-year measurement window. The stock's -81.9% 3-year return lags both the company's own peer group (by 44.4pp) and the IHI — iShares US Medical Devices ETF (by 81.6pp), both well above their respective policy triggers. The 5-year record confirms sustained underperformance, so the mitigant does not apply.
Mr. Scannell joined in February 2021, giving him full overlap with the 3-year TSR measurement period. NovoCure's -81.9% 3-year return lags the company-disclosed peer group by 44.4 percentage points, well above the 20-point trigger, and the IHI — iShares US Medical Devices ETF gap of 81.6 points also far exceeds the 30-point ETF threshold. The 5-year gap likewise exceeds the threshold, confirming the underperformance is not transient.
Mr. Vernon has served since 2006 and has been Lead Independent Director since 2016, giving him the longest tenured independent role on the board and full accountability for the sustained underperformance. The 3-year peer-group TSR gap of -44.4 percentage points and the IHI — iShares US Medical Devices ETF gap of -81.6 percentage points are both far above their respective thresholds, and the 5-year comparison confirms the decline is not a recent anomaly.
For Analysis
Ms. Cordova joined the board as CEO nominee and is exempt from the TSR trigger as a first-time nominee with no prior board tenure at NovoCure.
Dr. Ocean joined the board in February 2023, just over 24 months before the June 2025 meeting, placing her at the boundary of the 24-month new-director exemption; given that her tenure covers less than half of the 3-year measurement window, the policy treats this as a flag but not an automatic AGAINST, and her limited time on the board means she cannot reasonably be held accountable for the pre-existing underperformance.
Ms. Stafford was elected in March 2023, approximately 26 months before the June 2025 meeting, placing her just outside the strict 24-month exemption window but covering less than half of the 3-year underperformance period; policy guidance directs a flag rather than an automatic AGAINST for directors whose tenure overlaps less than half the underperformance period, so a FOR vote is appropriate.
Eight of eleven director nominees receive AGAINST votes due to NovoCure's severe and sustained stock underperformance: a 3-year return of -81.9% that trails the company's own disclosed peer group median by 44.4 percentage points (threshold: 20pp for negative absolute TSR) and lags the IHI — iShares US Medical Devices ETF by 81.6 percentage points (threshold: 30pp). The 5-year record (-92.0% absolute, -41.1pp below peer median) confirms this is not a transient trough, eliminating the 5-year mitigant for all long-tenured directors. First-time nominee Ashley Cordova and recently-appointed directors Allyson Ocean and Kristin Stafford receive FOR votes, as their limited tenure means they cannot fairly be held accountable for prior-period underperformance.
Say on Pay
✓ FORCEO
Asaf Danziger
Total Comp
$1,539,088
Prior Support
98.2%%
The outgoing CEO's total reported compensation of approximately $1.54 million is modest for a medical device company of NovoCure's size and market cap, and sits well within benchmark ranges for a CEO role at a ~$1.2B market cap healthcare company. The pay mix includes meaningful performance-based equity for executives other than the CEO (who was covered by a 2020 long-term performance award granted in lieu of annual equity), with one-third options, one-third time-vested restricted stock, and one-third performance stock awards, satisfying the policy's requirement that at least 50-60% of compensation be variable. Prior Say on Pay support was 98.2% at the 2024 annual meeting, well above the 70% threshold that would require a response, and the compensation structure shows genuine pay-for-performance features including clawback provisions and double-trigger change-in-control terms.
Auditor Ratification
✓ FORAuditor
Kost Forer Gabbay & Kasierer (member of Ernst & Young Global)
Tenure
22 yrs
Audit Fees
$948,000
Non-Audit Fees
$57,551
Non-audit fees of $57,551 represent approximately 6.1% of audit fees of $948,000, well below the 50% threshold that would raise independence concerns. EY Global's tenure since 2003 is approximately 22 years, below the 25-year trigger for a mandatory AGAINST vote. No material restatements were identified, and EY Global (a Big 4 network firm) is clearly adequate for NovoCure's size and complexity.
Overall Assessment
The 2025 NovoCure annual meeting presents a contentious director election ballot: eight of eleven nominees receive AGAINST votes due to NovoCure's catastrophic stock performance (-81.9% over three years, trailing the company's own peer group by 44.4 percentage points and the IHI — iShares US Medical Devices ETF by 81.6 percentage points), with only the incoming CEO and two recently-joined directors receiving FOR votes. The auditor ratification and Say on Pay proposals both pass policy screens cleanly, as auditor fees and independence metrics are well within acceptable ranges and the CEO's pay level is modest and well-structured.
Compensation Peer Group
14 companies disclosed in 2025 proxy filing